ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.341,13
0,74%
S&P 500
5.464,62
-0,16%
US Dollar vs BRL
5,4321
-0,20%
Bitcoin
64.109,41
-0,21%
Brent Oil
84,39
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Zymeworks Inc (ZYME)

  7. Zymeworks Inc (ZYME) Notícias

ZYME

Zymeworks (ZYME)

Zymeworks Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:ZYME
DataHoraFonteTítuloCódigoCompanhia
29/06/202317:12Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
21/06/202317:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ZYMEZymeworks Inc
12/06/202317:26Edgar (US Regulatory)Amended Securities Registration (section 12(b)) (8-a12b/a)NYSE:ZYMEZymeworks Inc
02/06/202320:23PR Newswire (US)Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract CancersNYSE:ZYMEZymeworks Inc
08/05/202318:20Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NYSE:ZYMEZymeworks Inc
28/04/202317:18Edgar (US Regulatory)Amended Annual Report (10-k/a)NYSE:ZYMEZymeworks Inc
07/03/202319:25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NYSE:ZYMEZymeworks Inc
14/02/202318:47Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:ZYMEZymeworks Inc
25/01/202310:30Business WireZymeworks Announces Participation in Upcoming Investor ConferencesNYSE:ZYMEZymeworks Inc
19/01/202309:45PR Newswire (US)Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal AdenocarcinomaNYSE:ZYMEZymeworks Inc
04/01/202318:15Business WireZymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023NYSE:ZYMEZymeworks Inc
03/01/202319:02Edgar (US Regulatory)Statement of Ownership (sc 13g)NYSE:ZYMEZymeworks Inc
28/12/202218:36Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NYSE:ZYMEZymeworks Inc
21/12/202209:30Business WireZymeworks Announces Participation in Upcoming Investor ConferenceNYSE:ZYMEZymeworks Inc
19/12/202209:00Business WireZymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of ZanidatamabNYSE:ZYMEZymeworks Inc
14/12/202218:15Business WireZanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers SymposiumNYSE:ZYMEZymeworks Inc
09/12/202210:00Business WireNew Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCSNYSE:ZYMEZymeworks Inc
05/12/202210:30Business WireZymeworks to Transfer Stock Listing to NasdaqNYSE:ZYMEZymeworks Inc
29/11/202210:30Business WireZymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz PharmaceuticalsNYSE:ZYMEZymeworks Inc
23/11/202200:41TipRanksAnalysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Enanta Pharmaceuticals (ENTA) and Zymeworks (ZYME)NYSE:ZYMEZymeworks Inc
21/11/202211:00Business WireZymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)NYSE:ZYMEZymeworks Inc
10/11/202201:35TipRanksSVB Securities Remains a Hold on Zymeworks (ZYME)NYSE:ZYMEZymeworks Inc
08/11/202218:22Business WireZymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsNYSE:ZYMEZymeworks Inc
01/11/202210:35TipRanksZymeworks (ZYME) was downgraded to a Hold Rating at H.C. WainwrightNYSE:ZYMEZymeworks Inc
24/10/202213:31TipRanksAnalysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Zymeworks (ZYME)NYSE:ZYMEZymeworks Inc
20/10/202209:30Business WireZymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology PlatformsNYSE:ZYMEZymeworks Inc
19/10/202208:31TipRanksZymeworks Rises on Jazz Pharma DealNYSE:ZYMEZymeworks Inc
19/10/202207:07Business WireZymeworks To Host Conference Call on Exclusive Licensing Agreement of ZanidatamabNYSE:ZYMEZymeworks Inc
19/10/202207:00PR Newswire (Canada)Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific AntibodyNYSE:ZYMEZymeworks Inc
18/10/202209:30Business WireZymeworks to Host Third Quarter Results Conference CallNYSE:ZYMEZymeworks Inc
 Apresentando as notícias mais relevantes sobre:NYSE:ZYME

Seu Histórico Recente

NASDAQI
HX551030GI
OMX Helsinki Precious Me...
TG
A28Z71
Carnival Corporation &
EU
NHWGR
Euronext NDR Hydrogen Wo...
BIT
P1YNN7
NLBNPIT1YNN7 20991231 20...
UNSW
TRANSPARENTETH
Transparent Token
LSE
46VF
Newday18 26 B
USOTC
NCBDY
Bandai Namco (PK)
BIT
P1L034
BNP Paribas Issuance
NASDAQI
OMXS30ESGASK
OMX Stockholm 30 ESG Res...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados